STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1269 by analyst upside · 2026-06-27
ATRC
AtriCure, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+55.7%
implied upside to consensus target
Current Price $30.18
Consensus Target $47.0
Bull Target $55.0
Bear Target $36.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
3
Buy
3
Hold
2
Sell
0
52-Week Low $25.36
52-Week High $43.18
YTD Return -23.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E 86.6x
EPS (TTM) $-0.11
PEG Ratio 10.00
Dividend Yield N/A
Revenue (TTM) $552M
Profit Margin -0.8%
52-WEEK RANGE
52-Week Low $25.36
52-Week High $43.18
Current Price $30.18
Bear Target $36.0
Bull Target $55.0
● Now $30.18 ● Target $47.0
TRADING DATA
Avg Volume 806K
YTD Return -23.1%
Analyst Count 8
Consensus Buy
Upside to Target +55.7%
Last Updated 2026-06-27

ANALYST SUMMARY

AtriCure, Inc. (ATRC) is currently trading at $30.18 with a Wall Street consensus price target of $47.0, implying potential upside of 55.7% over the next 12 months. 8 analysts currently cover ATRC, with a consensus rating of Buy — 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $55.0, while the most cautious has a target of $36.0.

ATRC operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 23.1% year-to-date and is currently trading near the lower end of its 52-week range of $25.36 – $43.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ATRC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-05-06 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-02-18 Building track record
UBS — Reiterated
Buy → Buy 2026-02-18 33% win rate (6 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-02-18 Building track record
Oppenheimer ↓ Downgrade
Outperform → Perform 2026-02-18 14% win rate (7 calls)
BTIG reit
Buy → Buy 2026-02-18 38% win rate (8 calls)
Needham reit
Buy → Buy 2026-02-12 20% win rate (5 calls)
JP Morgan — Reiterated
Overweight → Overweight 2025-12-16 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →